Avecia completes sales of its Pharmaceuticals business unit
Advertisement
Avecia announced that it has completed the sale of its Pharmaceuticals custom synthesis business to Nicholas Piramal India Limited (NPIL), having obtained all necessary approvals. This successfully concludes a sale agreement previously announced on 27th October 2005.
NPIL has paid GBP 9.5 million in cash for the entire Pharmaceuticals custom synthesis business which will be used to fund the UK pension fund deficit of Avecia Pharmaceuticals Limited.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.